EN DE
Watch Radiant Innovation for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Radiant Innovation (3373) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Radiant Innovation stock NT$15.10, price NT$15.65, that is 3.5% below the price, quality 44 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0003373007

RI Radiant Innovation logo Thin data Nov 16, 2026

Radiant Innovation

3373 · TWO

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Revenue last quarter +20% vs. a year ago. 
Fair value NT$15.10 · Fairly valued 
Quality 44/100 
0.6% dividend yield · Token dividend
Mixed vs. peers (4/10) 
Falling price (downtrend) 
Weak Growth (revenue 5y −31.7 %/yr in TWD) 
Loss-making · -8.6% net margin (TTM) 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Radiant Innovation for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

NT$54.37 NT$15.65 Fair Value NT$15.10 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range NT$15.65 – NT$54.37 · fair‑value band NT$11.32 – NT$18.87 · the NT$15.65 price screens above the NT$15.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Radiant Innovation in your weekly email

Every Wednesday you see whether Radiant Innovation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Radiant Innovation Inc. engages in the design and development of infrared technology products in Taiwan, Japan, and Germany. It offers medical infrared thermometers, including infrared ear, non-contact forehead, and multi-function thermometers, as well as probe cover; and CO2 monitors.

Show moreShow less

The company also offers industrial infrared thermometers, infrared precision thermal imagers, infrared precision gas monitors and other components. Radiant Innovation Inc. was founded in 1989 and is headquartered in Hsinchu City, Taiwan.

Stock analysis

Radiant Innovation (3373) currently trades at NT$15.65, while our estimate is NT$15.10, so the stock looks roughly fairly valued today (gap 3.6%).

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: NT$11.32 (bear) to NT$18.87 (bull), the price of NT$15.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Radiant Innovation reported revenue of 388M TWD in FY2025 versus 985M TWD in FY2021, a compound −20.8%/yr. Reported net income was −60.4M TWD in FY2025.

Key figures

Market cap 745M TWD (≈ $22.6M) Micro · P/S ratio 1.87 · EPS (TTM) NT$-0.74 · Dividend yield 0.6% · Net margin −8.6% · Return on equity −4.5% · Return on assets (EBIT) −2.3% (5-year average) · Operating margin −6.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −4%, 3373 screens richer than that median.

Fair Value

Bear NT$11.32 Fair Value NT$15.10 Bull NT$18.87
Price NT$15.65 · Downside -3.5%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 88
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 65
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
36.4% (2020) → −18.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 3373, get fair value alerts →

Compare Radiant Innovation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 399 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −3.5% · Above median
Profitability
Return on assets −7.0% · Below median
Net margin (12 months) −8.6% · Below median
Operating margin (12 months) −6.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 19.5% · Above median
Dividend yield (12 months) 0.6% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.94× · Cheapest 25%
P/S (12 months) 1.82× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 19
FUTURE (revenue growth)98 · sector 41
PAST (return on equity)0 · sector 2
HEALTH (low debt)–
DIVIDEND (yield)13 · sector 35

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $310.00 $341.00 +10% vs 3373
Boston Scientific Corporation BSX $41.98 $46.18 +10% vs 3373
DexCom, Inc DXCM $79.32 $87.25 +10% vs 3373
STERIS plc STE $255.76 $281.34 +10% vs 3373
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥183.81 ¥197.34 +7% vs 3373
GE HealthCare Technologies Inc GEHC $80.64 $69.92 −13% vs 3373
Edwards Lifesciences Corporation EW $101.85 $81.94 −20% vs 3373
Medtronic plc MDT $99.94 $74.89 −25% vs 3373
Abbott Laboratories, ABT $103.00 $75.28 −27% vs 3373
Koninklijke Philips N.V PHIA €26.39 €15.23 −42% vs 3373

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Radiant Innovation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Radiant Innovation Fair Value". https://www.fairvalue-calculator.com/stock/3373

Frequently asked questions

Is Radiant Innovation (3373) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is NT$15.10 versus a price of NT$15.65, about 4% lower (fairly valued).
What is the fair value of 3373?
Our estimate for Radiant Innovation is NT$15.10 (as of Nov 16, 2026), built from audited fundamentals. The current price: NT$15.65.
What is the quality score of 3373?
Radiant Innovation has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Radiant Innovation (3373)?
We do not set a price target; the yardstick is our estimate of NT$15.10 (as of Nov 16, 2026). Cautious scenario NT$11.32, optimistic scenario NT$18.87. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Radiant Innovation stock forecast for 2026?
Our estimate puts fair value at NT$15.10, about 4% lower versus a price of NT$15.65 (fairly valued). Cautious scenario NT$11.32, optimistic scenario NT$18.87. The calculation is refreshed regularly with new filings.
What is the revenue of Radiant Innovation (3373)?
Radiant Innovation reported trailing-twelve-month revenue of about 409M TWD (latest available figure, as of Nov 16, 2026).
Does Radiant Innovation pay a dividend?
Radiant Innovation currently shows a dividend yield of 0.64% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Radiant Innovation (3373) and when is the ex-dividend date?
Radiant Innovation pays a dividend of NT$0.1 per share a year, a dividend yield of 0.6%. The last ex-dividend date was Aug 28, 2026. Our assessment: Token dividend. At a yield of 0.6% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.6% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Radiant Innovation (3373)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Radiant Innovation it is NT$15.10 per share (as of Nov 16, 2026), against a price of NT$15.65.
Is Radiant Innovation stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 3373 trades above its calculated fair value: price NT$15.65, fair value NT$15.10, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3373?
No. The price is what the market pays today (NT$15.65); the fair value is what the company's own numbers justify (NT$15.10). For Radiant Innovation the two are NT$0.547 per share apart. That gap is exactly why we show both numbers side by side.
How much is Radiant Innovation worth?
The market values Radiant Innovation at about 745M TWD (market capitalisation, as of Nov 16, 2026). Per share that is NT$15.65; our models calculate a fair value of NT$15.10 per share.
What do the bullish and bearish scenarios say about 3373?
Our models span a range for Radiant Innovation: cautious scenario NT$11.32, base NT$15.10, optimistic NT$18.87 per share (as of Nov 16, 2026, price NT$15.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Radiant Innovation (3373)?
Balance-sheet figures for Radiant Innovation (as of Nov 16, 2026): return on equity −4.5%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 3373 from its 52-week high?
Radiant Innovation trades at NT$15.65, about 24% below its 52-week high of NT$20.65 and at the low of NT$15.65 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of NT$15.10 is for.
Which stocks are comparable to Radiant Innovation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Radiant Innovation stock attractive at the current price?
The data as of Nov 16, 2026: price NT$15.65, calculated fair value NT$15.10 (−4%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Radiant Innovation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Radiant Innovation (3373)?
The closing price on Nov 20, 2026 was NT$15.65. Our estimate is NT$15.10, about 4% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Radiant Innovation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Radiant Innovation

How large is the market capitalisation of Radiant Innovation (3373)?
The market capitalisation of Radiant Innovation is 745M TWD (≈ $22.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Radiant Innovation (3373)?
The price-to-sales ratio of Radiant Innovation is 1.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Radiant Innovation (3373)?
Earnings per share at Radiant Innovation are NT$-0.74. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Radiant Innovation (3373)?
The dividend yield of Radiant Innovation is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Radiant Innovation (3373)?
The net margin of Radiant Innovation is −8.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Radiant Innovation (3373)?
The return on equity (ROE) of Radiant Innovation is −4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Radiant Innovation (3373)?
On an EBIT basis the return on assets of Radiant Innovation is −2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Radiant Innovation (3373)?
The operating margin of Radiant Innovation is −6.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Radiant Innovation (3373)?
Revenue at Radiant Innovation is growing 19.5% in the last quarter versus the same quarter a year earlier (3y avg −11.8%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at Radiant Innovation (3373)?
Earnings per share at Radiant Innovation are down 74.4% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
How much free cash flow does Radiant Innovation (3373) generate?
The free cash flow of Radiant Innovation is −5.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Radiant Innovation in the live analysis

One click puts Radiant Innovation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.